FindTrial
Sign In

Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-Investigation of the clinical condition and safety in patients with cervical dystonia

Post-marketing surveillance of administration of botulinum toxin type B(NerBloc )-Investigation of the clinical condition and safety in patients with cervical dystonia (Study NB01S)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222127
Enrollment
Unknown
Registered
2013-06-28
Start date
2013-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical dystonia

Interventions

investigational material(s) Generic name etc : botulinum toxin type B(NerBloc ) INN of investigational material : Therapeutic category code : 122 Skeletal muscle relaxants Dosage and Administration f

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients with cervical dystonia and administrated NerBloc

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Whole improvement level Whole improvement level 1.Eminent improvement. 2. Improvement. 3. Improvement a little invariability. 5. Exacerbation. 6. It is not possible to judge.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026